Ikashi Screener(USA)

PFIZER INC

PFE · CIK 0000078003 · NYSE · Healthcare (Pharmaceutical Preparations)

Overview — PFIZER INC

Revenue (TTM)
$63.70B
Net Income (TTM)
$4.36B
Total Assets
$201.13B
Total Debt
$60.49B

Pros

  • Operating cash flow comfortably exceeds reported net income

Cons

  • Revenue has declined over the last 5 years

Chart

No price data yet — run npm run ingest:prices in apps/api.

Revenue & Net Income

RevenueNet Income
050B100B150B200B2016201720182019202020212022202320242025TTM

Peers

Sector: Healthcare. Sector is derived from SEC's SIC code, not GICS. Click a column to sort.

CompanyMarket Cap ▼Revenue (TTM) Net Income (TTM) Net Margin ROE Debt/Equity
JNJ JOHNSON & JOHNSON$660.42B$99.33B$16.09B16.2%19.7%0.44
ABBV AbbVie Inc.—$64.39B$6.32B9.8%-106.4%—
MRK Merck & Co., Inc.—$66.57B$3.17B4.8%7.6%1.28
PFE PFIZER INC—$63.70B$4.36B6.8%5.1%0.71
MMM 3M CO—$25.25B$3.58B14.2%85.9%3.01

Quarterly results

Line itemOct 22Apr 23Jul 23Oct 23Mar 24Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26
Revenue$22.64B$18.49B$13.01B$13.49B$14.88B$13.28B$17.70B$13.71B$14.65B$16.65B$14.45B$15.03B
Net Income$8.62B$5.56B$2.34B-$2.38B$3.12B$48.00M$4.47B$2.97B$2.93B$3.55B$2.70B-$248.00M
Operating Cash Flow—$1.21B——$1.09B——$2.33B——$2.62B—

Profit & Loss

Line item2016201720182019202020212022202320242025TTM
Revenue$52.82B$52.55B$53.65B$51.75B$41.91B$81.29B$101.17B$59.55B$63.63B$62.58B$63.70B
Net Income$7.25B$21.36B$11.19B$16.30B$9.65B$22.02B$31.41B$2.16B$8.06B$7.81B$4.36B

Balance Sheet

Line item2016201720182019202020212022202320242025TTM
Total Assets$171.62B$171.80B$159.42B$167.59B$154.23B$181.48B$197.21B$226.50B$213.40B$208.16B$201.13B
Total Liabilities$111.78B$100.14B$95.66B$104.15B$90.76B$104.01B$101.29B$137.21B$124.90B$121.39B$115.64B
Total Equity$59.84B$71.66B$63.76B$63.45B$63.47B$77.46B$95.92B$89.29B$88.50B$86.78B$85.49B
Total Debt$31.40B$33.54B$32.91B$35.95B$37.13B$36.20B$32.88B$61.54B$57.41B$61.64B$60.49B
Shares Outstanding——————————5,699,673,589

Cash Flow

Line item2016201720182019202020212022202320242025TTM
Operating Cash Flow$16.19B$16.80B$15.83B$12.59B$14.40B$32.58B$29.27B$8.70B$12.74B$11.70B$11.98B
Capex$1.82B$1.96B$2.04B$2.18B$2.25B$2.71B$3.24B$3.91B$2.91B$2.63B$2.50B

Ratios

Profitability

Ratio2016201720182019202020212022202320242025TTM
Net margin13.7%40.6%20.9%31.5%23.0%27.1%31.0%3.6%12.7%12.5%6.8%
Return on equity12.1%29.8%17.5%25.7%15.2%28.4%32.7%2.4%9.1%9.0%5.1%
Return on assets4.2%12.4%7.0%9.7%6.3%12.1%15.9%1.0%3.8%3.8%2.2%
Return on capital employed (ROCE)———————————
Debt / Equity0.520.470.520.570.590.470.340.690.650.710.71
FCF margin27.2%28.3%25.7%20.1%29.0%36.7%25.7%8.0%15.5%14.5%14.9%

Working capital

Ratio2016201720182019202020212022202320242025TTM
Debtor days57d57d55d62d69d52d40d71d66d69d72d
Inventory days201d246d244d296d338d107d95d149d222d242d212d
Payable days134d151d152d151d181d66d72d98d115d119d98d
Cash conversion cycle123d152d147d207d226d93d63d122d172d192d186d
Working capital days54d74d123d-32d80d76d33d-27d42d34d50d

Investors

US filings have no equivalent to India's Promoter/FII/DII shareholding-pattern disclosure. Shown below are the closest real US sources: Form 4 insider transactions and Form 13F institutional holders (matched by issuer name, not CUSIP — a few companies, especially ones that changed their legal name, may be incomplete).

Institutional Holders

No data yet — run npm run ingest:institutions in apps/api.

Insider Trades

PersonRelationshipDateTypeSharesPrice
BOURLA ALBERTChairman & CEO8/12/2026Purchase38,000$26.34
DAMICO JENNIFER B.SVP & Controller8/5/2026Sale3,278$25.40
BLAYLOCK RONALD EDirector8/5/2026Purchase39,231$25.46
Buckley Mortimer JDirector8/5/2026Purchase37,632$25.52

Documents